ArQule, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “ArQule, Inc. - Product Pipeline Review - 2012” provides data on the ArQule, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ArQule, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ArQule, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of ArQule, Inc.; ArQule, Inc. - Key Therapeutics; ArQule, Inc. - Pipeline Overview and Promising Molecules; ArQule, Inc. - News; ArQule, Inc. - Latest Updates; ArQule, Inc. - Pipeline; ArQule, Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “ArQule, Inc. - Product Pipeline Review - 2012” provides data on the ArQule, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ArQule, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ArQule, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- ArQule, Inc. - Brief ArQule, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ArQule, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ArQule, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ArQule, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate ArQule, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ArQule, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ArQule, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ArQule, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ArQule, Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of ArQule, Inc.; ArQule, Inc. - Key Therapeutics; ArQule, Inc. - Pipeline Overview and Promising Molecules; ArQule, Inc. - News; ArQule, Inc. - Latest Updates; ArQule, Inc. - Pipeline; ArQule, Inc. - Discontinued/Dormant Projects
ArQule, Inc. Snapshot
ArQule, Inc. Overview
Key Information
Key Facts
ArQule, Inc. – Research and Development Overview
Key Therapeutic Areas
ArQule, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
ArQule, Inc. – Pipeline Products Glance
ArQule, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
ArQule, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ArQule, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ArQule, Inc. – Drug Profiles
ARQ 087
Product Description
Mechanism of Action
R&D Progress
ARQ 197
Product Description
Mechanism of Action
R&D Progress
ARQ 197 + Cetuximab + Irinotecan
Product Description
Mechanism of Action
R&D Progress
ARQ 197 + Erlotinib
Product Description
Mechanism of Action
R&D Progress
ARQ 197 + Sorafenib
Product Description
Mechanism of Action
R&D Progress
ARQ 621
Product Description
Mechanism of Action
R&D Progress
ARQ 736
Product Description
Mechanism of Action
R&D Progress
ARQ 761
Product Description
Mechanism of Action
R&D Progress
Non-ATP Competitive Kinase Inhibitors
Product Description
Mechanism of Action
R&D Progress
ArQule, Inc. – Pipeline Analysis
ArQule, Inc. – Pipeline Products by Therapeutic Class
ArQule, Inc. – Pipeline Products By Target
ArQule, Inc. – Pipeline Products by Route of Administration
ArQule, Inc. – Pipeline Products By Mechanism of Action
ArQule, Inc. – Recent Pipeline Updates
ArQule, Inc. - Dormant Projects
ArQule, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ARQ 171
Baxter International Inc. – Company Statement
Baxter International Inc. – Locations And Subsidiaries
Head Office
Baxter International Inc., Recent Developments
Baxter International Inc.- Press Release
May 18, 2012: ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase III Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer
May 17, 2012: ArQule And Daiichi Sankyo Announce Positive Phase II Clinical Data with Tivantinib in Hepatocellular Carcinoma At ASCO 2012 Annual Meeting
Mar 29, 2012: ArQule To Present Clinical And Preclinical Data On Tivantinib At AACR 102nd Annual Meeting
Jan 17, 2012: ArQule's Tivantinib Meets Primary Endpoint In Phase II Trial Of Second-Line Hepatocellular Carcinoma
Nov 16, 2009: Drug Discovery Capabilities Of ArQule Kinase Inhibitor Platform Presented At AACR-NCI-EORTC Conference
Nov 16, 2009: Drug Discovery Capabilities Of ArQule Kinase Inhibitor Platform Presented At AACR-NCI-EORTC Conference
Oct 14, 2009: European Medicines Evaluation Agency Grants Orphan Drug Designation To ARQ 197 For Treatment Of Soft Tissue Sarcoma
Apr 20, 2009: ArQule Presents Three Studies At AACR 100th Annual Meeting 2009
Mar 26, 2009: ArQule Enrolls First Patient In Phase 1 Trial With ARQ 621, An Eg5 Inhibitor
Financial Deals Landscape
ArQule, Inc., Deals Summary
ArQule, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
ArQule Enters Into An Agreement With Daiichi Sankyo
ArQule Enters Into Research Agreement With Boston Biomedical
Roche Enters Into Co-Development Agreement With ArQule
Licensing Agreements
Daiichi Sankyo Exercises Option To Obtain License For ARQ 092 From ArQule
ArQule Expands Its Licensing Agreement With Daiichi Sankyo
ArQule Enters Into Licensing Agreement With Daiichi Sankyo
Kyowa Hakko Kogyo Enters Into Licensing Agreement With ArQule
Equity Offering
ArQule Completes Public Offering Of Common Stock For $60 Million
ArQule Completes An Underwritten Public Offering Of Its Common Stock For $49.51 Million
ArQule Completes Public Offering Of $58 Million
ArQule Completes Public Offering Of $30 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
ArQule, Inc., Key Information
ArQule, Inc., Key Facts
ArQule, Inc. – Pipeline by Indication, 2012
ArQule, Inc. – Pipeline by Stage of Development, 2012
ArQule, Inc. – Monotherapy Products in Pipeline, 2012
ArQule, Inc. – Combination Treatment Modalities in Pipeline, 2012
ArQule, Inc. – Phase III, 2012
ArQule, Inc. – Phase II, 2012
ArQule, Inc. – Phase I, 2012
ArQule, Inc. – Pre-Clinical, 2012
ArQule, Inc. – Pipeline By Therapeutic Class, 2012
ArQule, Inc. - Pipeline By Target, 2012
ArQule, Inc. – Pipeline By Route of Administration, 2012
ArQule, Inc. – Pipeline Products By Mechanism of Action, 2012
ArQule, Inc. – Recent Pipeline Updates, 2012
ArQule, Inc. - Dormant Developmental Projects,2012
ArQule, Inc. - Discontinued Pipeline Products, 2012
ArQule, Inc., Deals Summary
ArQule Enters Into An Agreement With Daiichi Sankyo
ArQule Enters Into Research Agreement With Boston Biomedical
Roche Enters Into Co-Development Agreement With ArQule
Daiichi Sankyo Exercises Option To Obtain License For ARQ 092 From ArQule
ArQule Expands Its Licensing Agreement With Daiichi Sankyo
ArQule Enters Into Licensing Agreement With Daiichi Sankyo
Kyowa Hakko Kogyo Enters Into Licensing Agreement With ArQule
ArQule Completes Public Offering Of Common Stock For $60 Million
ArQule Completes An Underwritten Public Offering Of Its Common Stock For $49.51 Million
ArQule Completes Public Offering Of $58 Million
ArQule Completes Public Offering Of $30 Million
LIST OF FIGURES
ArQule, Inc. – Pipeline by Indication, 2012
ArQule, Inc. – Pipeline by Stage of Development, 2012
ArQule, Inc. – Monotherapy Products in Pipeline, 2012
ArQule, Inc. – Combination Treatment Modalities in Pipeline, 2012
ArQule, Inc. - Pipeline By Target, 2012
ArQule, Inc. – Pipeline By Route of Administration, 2012
ArQule, Inc. - Pipeline Products By Mechanism of Action, 2012
ArQule, Inc. Overview
Key Information
Key Facts
ArQule, Inc. – Research and Development Overview
Key Therapeutic Areas
ArQule, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
ArQule, Inc. – Pipeline Products Glance
ArQule, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
ArQule, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ArQule, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ArQule, Inc. – Drug Profiles
ARQ 087
Product Description
Mechanism of Action
R&D Progress
ARQ 197
Product Description
Mechanism of Action
R&D Progress
ARQ 197 + Cetuximab + Irinotecan
Product Description
Mechanism of Action
R&D Progress
ARQ 197 + Erlotinib
Product Description
Mechanism of Action
R&D Progress
ARQ 197 + Sorafenib
Product Description
Mechanism of Action
R&D Progress
ARQ 621
Product Description
Mechanism of Action
R&D Progress
ARQ 736
Product Description
Mechanism of Action
R&D Progress
ARQ 761
Product Description
Mechanism of Action
R&D Progress
Non-ATP Competitive Kinase Inhibitors
Product Description
Mechanism of Action
R&D Progress
ArQule, Inc. – Pipeline Analysis
ArQule, Inc. – Pipeline Products by Therapeutic Class
ArQule, Inc. – Pipeline Products By Target
ArQule, Inc. – Pipeline Products by Route of Administration
ArQule, Inc. – Pipeline Products By Mechanism of Action
ArQule, Inc. – Recent Pipeline Updates
ArQule, Inc. - Dormant Projects
ArQule, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ARQ 171
Baxter International Inc. – Company Statement
Baxter International Inc. – Locations And Subsidiaries
Head Office
Baxter International Inc., Recent Developments
Baxter International Inc.- Press Release
May 18, 2012: ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase III Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer
May 17, 2012: ArQule And Daiichi Sankyo Announce Positive Phase II Clinical Data with Tivantinib in Hepatocellular Carcinoma At ASCO 2012 Annual Meeting
Mar 29, 2012: ArQule To Present Clinical And Preclinical Data On Tivantinib At AACR 102nd Annual Meeting
Jan 17, 2012: ArQule's Tivantinib Meets Primary Endpoint In Phase II Trial Of Second-Line Hepatocellular Carcinoma
Nov 16, 2009: Drug Discovery Capabilities Of ArQule Kinase Inhibitor Platform Presented At AACR-NCI-EORTC Conference
Nov 16, 2009: Drug Discovery Capabilities Of ArQule Kinase Inhibitor Platform Presented At AACR-NCI-EORTC Conference
Oct 14, 2009: European Medicines Evaluation Agency Grants Orphan Drug Designation To ARQ 197 For Treatment Of Soft Tissue Sarcoma
Apr 20, 2009: ArQule Presents Three Studies At AACR 100th Annual Meeting 2009
Mar 26, 2009: ArQule Enrolls First Patient In Phase 1 Trial With ARQ 621, An Eg5 Inhibitor
Financial Deals Landscape
ArQule, Inc., Deals Summary
ArQule, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
ArQule Enters Into An Agreement With Daiichi Sankyo
ArQule Enters Into Research Agreement With Boston Biomedical
Roche Enters Into Co-Development Agreement With ArQule
Licensing Agreements
Daiichi Sankyo Exercises Option To Obtain License For ARQ 092 From ArQule
ArQule Expands Its Licensing Agreement With Daiichi Sankyo
ArQule Enters Into Licensing Agreement With Daiichi Sankyo
Kyowa Hakko Kogyo Enters Into Licensing Agreement With ArQule
Equity Offering
ArQule Completes Public Offering Of Common Stock For $60 Million
ArQule Completes An Underwritten Public Offering Of Its Common Stock For $49.51 Million
ArQule Completes Public Offering Of $58 Million
ArQule Completes Public Offering Of $30 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
ArQule, Inc., Key Information
ArQule, Inc., Key Facts
ArQule, Inc. – Pipeline by Indication, 2012
ArQule, Inc. – Pipeline by Stage of Development, 2012
ArQule, Inc. – Monotherapy Products in Pipeline, 2012
ArQule, Inc. – Combination Treatment Modalities in Pipeline, 2012
ArQule, Inc. – Phase III, 2012
ArQule, Inc. – Phase II, 2012
ArQule, Inc. – Phase I, 2012
ArQule, Inc. – Pre-Clinical, 2012
ArQule, Inc. – Pipeline By Therapeutic Class, 2012
ArQule, Inc. - Pipeline By Target, 2012
ArQule, Inc. – Pipeline By Route of Administration, 2012
ArQule, Inc. – Pipeline Products By Mechanism of Action, 2012
ArQule, Inc. – Recent Pipeline Updates, 2012
ArQule, Inc. - Dormant Developmental Projects,2012
ArQule, Inc. - Discontinued Pipeline Products, 2012
ArQule, Inc., Deals Summary
ArQule Enters Into An Agreement With Daiichi Sankyo
ArQule Enters Into Research Agreement With Boston Biomedical
Roche Enters Into Co-Development Agreement With ArQule
Daiichi Sankyo Exercises Option To Obtain License For ARQ 092 From ArQule
ArQule Expands Its Licensing Agreement With Daiichi Sankyo
ArQule Enters Into Licensing Agreement With Daiichi Sankyo
Kyowa Hakko Kogyo Enters Into Licensing Agreement With ArQule
ArQule Completes Public Offering Of Common Stock For $60 Million
ArQule Completes An Underwritten Public Offering Of Its Common Stock For $49.51 Million
ArQule Completes Public Offering Of $58 Million
ArQule Completes Public Offering Of $30 Million
LIST OF FIGURES
ArQule, Inc. – Pipeline by Indication, 2012
ArQule, Inc. – Pipeline by Stage of Development, 2012
ArQule, Inc. – Monotherapy Products in Pipeline, 2012
ArQule, Inc. – Combination Treatment Modalities in Pipeline, 2012
ArQule, Inc. - Pipeline By Target, 2012
ArQule, Inc. – Pipeline By Route of Administration, 2012
ArQule, Inc. - Pipeline Products By Mechanism of Action, 2012